- Home
- TVGN vs TIL Comparison
TVGN vs TIL Comparison
Compare TVGN & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TVGN | TIL |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.9M | 74.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TVGN | TIL |
|---|---|---|
| Price | $0.28 | $8.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $5.00 | ★ $125.00 |
| AVG Volume (30 Days) | ★ 635.2K | 68.0K |
| Earning Date | 04-01-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $5.67 |
| 52 Week High | $1.69 | $42.79 |
Technical Indicators
Market Signals| Indicator | TVGN | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 32.16 | 49.46 |
| Support Level | $0.23 | $7.51 |
| Resistance Level | $0.26 | $7.87 |
| Average True Range (ATR) | 0.03 | 0.34 |
| MACD | -0.00 | 0.24 |
| Stochastic Oscillator | 22.18 | 100.00 |
Price Performance
Historical ComparisonAbout TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.